Robert L. Ferris Laboratory
Department of Otolaryngology, Head and Neck Cancer
Hillman Cancer Center Research Pavilion, Lab# 2.19
University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, Pennsylvania,15213-1863,USA
 | smraghvendra@yahoo.co.in |
Conference and meetings:
“American Association of Immunologist meeting”: 2014. Cancer Immunbiology session. Abstract. Cancer Immunobiology session: Natural killer: dendritic cell activation usining anti-CD137 mAb improves cetuximab mediated innate and adaptive immune responses in head and neck cancer (TUM7P.948). Raghvendra M. Srivastava*, Hyun-bae Jie, Jing Li, Robert L. Ferris. Department of otolaryngology, Department of Immunology, University of Pittsburgh, Journal of Immunology. 2014 192:203.30.
“American Association of Immunologist meeting”: 2014. Immunosuppression in tumor microenvironment session. Abstract. CTLA-4 regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916). Hyun-bae Jie, Patrick Schuler, Raghvendra M. Srivastava, Athanassios Argiris, Soldano Ferrone, Theresa Whiteside, Robert Ferris. Department of otolaryngology, Department of Immunology, University of Pittsburgh, Journal of Immunology. 2014 192:71.40.
Society for immunotherapy of cancer”: 2013. Advances in Cancer Immunotherapy, CME-Certified, Regional program in collaboration with University of Pittsburgh Cancer Institute, partner with UPMC. December 07, 2013, Ronald Herberman Conference Center, UPMC Cancer Pavillion, UPMC Shadyside, Pittsburgh, PA
“Translational research cancer centers consortium”: 2013. Feb, 20-22 2013, Seven Springs, PA. (Poster presentation). Session 2-2, Defective Signaling in the Tumor Microenvironment. Poster abstract. Raghvendra M. Srivastava, Jie Hyun-bae, Soldano Ferrone, Robert L. Ferris.
“Society for immunotherapy of cancer”: 2013. 28th annual meeting. November 08-10, 2013, Abstract. STAT-1 contributes to HLA-class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer. Raghvendra M. Srivastava, Hyun-bae Jie, Soldano Ferrone, Robert L. Ferris. Journal of Immunotherapy of Cancer 2013,1 (Suppl 1):P190 doi:10.1186/2051-1426-1-S1-P190.
“Society for immunotherapy of cancer”: 2013.” 28th annual meeting. November 08-10, 2013, Abstract. TIM-3 positive cells are not exhausted but activated cells in tumor microenvironment. Hyun-bae Joe, Jing Li, Ragvendra M. Srivastava, Robert L. Ferris. Journal of Immunotherapy of Cancer 2013, 1(Supple 1): P190 doi:10.1186/2051-1426-1-S1-P190.
“American Association of Cancer Research” Cancer Immunotherapy: 2012. Abstract LB-431: Augmented induction of tumor antigen-specific CTL by cetuximab in head and neck cancer patients does not correlate with Fcg receptor IIIa genotype, but relies on NK:DC cross talk mediated by interferon-g and NKG2D. Christopher A. Lord, Raghvendra M. Srivastava, Steve C. Lee, Pedro A. Andrade Filho, Sandra P. Gibson, William E. Gooding, Soldano Ferrone, and Robert L. Ferris. AACR 103rd Annual Meeting 2012- Mar 31-Apr 4, 2012; Chicago, IL.
“American Association of Cancer Research” Special Conference, Tumor Immunology: 2012. Multidisciplinary Science Driving Basic and Clinical Advances. "Patterns and kinetics of interferon-γ secretion by natural killer cell subsets co-cultured with cetuximab-coated head and neck cancer cells and dendritic cells".The CD56dimCD16bright, and not the CD56brightCD16dim NK cell subset is the primary mediator of interferon- secretion in response to cetuximab-coated head and neck cancer cells. Lord CA, Srivastava RM, Ferris RL. December 2-5, 2012 in Miami, FL
“Society for immunotherapy of cancer”: 2012. Oct.24-28rth 2012, at Bethesda, MD. (Poster presentation). Poster abstract # 180. Raghvendra M. Srivastava, Sandra P. Gibson, Andrés López-Albaitero, Pedro A. Andrade Filho, Christopher A. Lord, Jie Hyun-bae, Soldano Ferrone and Robert L. Ferris.
“Society for immunotherapy of cancer”: 2012. Epidermal Growth Factor Receptor Signaling Facilitates Immune Escape Function in Head and Neck Cancer .Raghvendra M. Srivastava*, Jie Hyun-bae*, Soldano Ferrone*, Robert L. Ferris*. *Department of Otolaryngology, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA; Surgery, Pathology, Immunology, University of Pittsburgh, Pittsburgh, PA. Head and neck cancer (HNC). J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 782.
“Society for immunotherapy of cancer”: 2012. Oct.24-28rth 2012, at Bethesda, MD. (Poster presentation). Poster abstract # 181. Raghvendra M. Srivastava, Jie Hyun-bae, Soldano Ferrone, Robert L. Ferris.
“Society for immunotherapy of cancer”: 2012. A Study of Immune Mechanisms of Action of Anti-epidermal Growth Factor Receptor Antibodies Cetuximab and Panitumumab and its Implication in Head and Neck Cancer Therapy, Raghvendra M. Srivastava*, Sandra P. Gibson*, Andres Lopez- Albaitero*, Jie Hyun-bae*, Soldao Ferronewzy, Robert L. Ferris*. *Otolaryngology, University of Pittsburgh, Pittsburgh, PA; Surgery, University of Pittsburgh, Pittsburgh, PA; Pathology, University of Pittsburgh, Pittsburgh, PA; Immunology, University of Pittsburgh, Pittsburgh, PA.J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 782.
“Society for immunotherapy of cancer”: 2012. Abstract. Inhibitory Receptors on Tumor Infiltrating Lymphocytes Reflect Aberrant TCR Triggering in the Tumor Microenvironment, Hyun-Bae Jie, Raghvendra Srivastava, Sandra Gibson, Robert L Ferris. Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA. Published in J Immunotherapy, Volume 35, Number 9, November–December 2012.p.786.
“Society for immunotherapy of cancer”: 2012. Abstract. Enrichment of CTLA4+CD39+CD25+FOXP3+ Regulatory T Cells in Head and Neck Cancer Patients is Promoted by Therapy With Cetuximab and Correlated With Clinical Outcome. Hyun-Bae Jie*, Patrick J. Schuler*, Fernando Concha-Benavente*, Raghvendra Srivastava*, Steve Lee*, Robert L. Ferris*. *Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA; Otorhinolaryngology, University Duisburg-Essen, Essen, Germany. J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 777.
“Society for immunotherapy of cancer”: 2012. Abstract. Enrichment of CTLA4+CD39+CD25+FOXP3+ Regulatory T Cells in Head and Neck Cancer Patients is Promoted by Therapy With Cetuximab and Correlated With Clinical Outcome. Hyun-Bae Jie*, Patrick J. Schuler*, Fernando Concha-Benavente*, Raghvendra Srivastava*, Steve Lee*, Robert L. Ferris*. *Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA; Otorhinolaryngology, University Duisburg-Essen, Essen, Germany. J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 777.
Poster presentation at University of Pittsburgh Cancer Institute Retreat: 2012, June 14, 2013 sponsored by UPCI.
Poster presentation at University of Pittsburgh Cancer Institute Retreat: 2012, June 21-22, 2012 sponsored by UPCI.
“Society for immunotherapy of cancer”: 2012.Oct.24-28th 2012, Bethesda, MD. (Poster presentation).
Poster presentation at University of Pittsburgh Cancer Institute Retreat: 2012. June 21-22, 2012 sponsored by UPCI.
Immunology series seminar at University of Pittsburgh: 2010. Nov18, 2010, Cetuximab activated NK cells enhance DC cross-priming of tumor antigen.
Current Trend in Drug Discovery Research: 2007. Feb 17-21st, 2007 at Central Drug research Institute, Lucknow (Poster presentation)
“All India Cell Biology Conference on Genome Biology”: 2004. held on Dec.1-3rd 2004, at Punjab University, Chandigarh.(Poster presentation)
“Current Excitement in Biology”: 2002. Nov. 24-30th 2002 at Centre for cellular and molecular biology, Hyderabad.
"Poster presentation on ‘National Science Day’: 2000. Feb 8rth, 2000 sponsored by Department of Biotechnology, Govt. of India at BHU Varanasi and won the first prize.
“American Association of Immunologist meeting”: 2014. Cancer Immunbiology session. Abstract. Cancer Immunobiology session: Natural killer: dendritic cell activation usining anti-CD137 mAb improves cetuximab mediated innate and adaptive immune responses in head and neck cancer (TUM7P.948). Raghvendra M. Srivastava*, Hyun-bae Jie, Jing Li, Robert L. Ferris. Department of otolaryngology, Department of Immunology, University of Pittsburgh, Journal of Immunology. 2014 192:203.30.
“American Association of Immunologist meeting”: 2014. Immunosuppression in tumor microenvironment session. Abstract. CTLA-4 regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916). Hyun-bae Jie, Patrick Schuler, Raghvendra M. Srivastava, Athanassios Argiris, Soldano Ferrone, Theresa Whiteside, Robert Ferris. Department of otolaryngology, Department of Immunology, University of Pittsburgh, Journal of Immunology. 2014 192:71.40.
Society for immunotherapy of cancer”: 2013. Advances in Cancer Immunotherapy, CME-Certified, Regional program in collaboration with University of Pittsburgh Cancer Institute, partner with UPMC. December 07, 2013, Ronald Herberman Conference Center, UPMC Cancer Pavillion, UPMC Shadyside, Pittsburgh, PA
“Translational research cancer centers consortium”: 2013. Feb, 20-22 2013, Seven Springs, PA. (Poster presentation). Session 2-2, Defective Signaling in the Tumor Microenvironment. Poster abstract. Raghvendra M. Srivastava, Jie Hyun-bae, Soldano Ferrone, Robert L. Ferris.
“Society for immunotherapy of cancer”: 2013. 28th annual meeting. November 08-10, 2013, Abstract. STAT-1 contributes to HLA-class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer. Raghvendra M. Srivastava, Hyun-bae Jie, Soldano Ferrone, Robert L. Ferris. Journal of Immunotherapy of Cancer 2013,1 (Suppl 1):P190 doi:10.1186/2051-1426-1-S1-P190.
“Society for immunotherapy of cancer”: 2013.” 28th annual meeting. November 08-10, 2013, Abstract. TIM-3 positive cells are not exhausted but activated cells in tumor microenvironment. Hyun-bae Joe, Jing Li, Ragvendra M. Srivastava, Robert L. Ferris. Journal of Immunotherapy of Cancer 2013, 1(Supple 1): P190 doi:10.1186/2051-1426-1-S1-P190.
“American Association of Cancer Research” Cancer Immunotherapy: 2012. Abstract LB-431: Augmented induction of tumor antigen-specific CTL by cetuximab in head and neck cancer patients does not correlate with Fcg receptor IIIa genotype, but relies on NK:DC cross talk mediated by interferon-g and NKG2D. Christopher A. Lord, Raghvendra M. Srivastava, Steve C. Lee, Pedro A. Andrade Filho, Sandra P. Gibson, William E. Gooding, Soldano Ferrone, and Robert L. Ferris. AACR 103rd Annual Meeting 2012- Mar 31-Apr 4, 2012; Chicago, IL.
“American Association of Cancer Research” Special Conference, Tumor Immunology: 2012. Multidisciplinary Science Driving Basic and Clinical Advances. "Patterns and kinetics of interferon-γ secretion by natural killer cell subsets co-cultured with cetuximab-coated head and neck cancer cells and dendritic cells".The CD56dimCD16bright, and not the CD56brightCD16dim NK cell subset is the primary mediator of interferon- secretion in response to cetuximab-coated head and neck cancer cells. Lord CA, Srivastava RM, Ferris RL. December 2-5, 2012 in Miami, FL
“Society for immunotherapy of cancer”: 2012. Oct.24-28rth 2012, at Bethesda, MD. (Poster presentation). Poster abstract # 180. Raghvendra M. Srivastava, Sandra P. Gibson, Andrés López-Albaitero, Pedro A. Andrade Filho, Christopher A. Lord, Jie Hyun-bae, Soldano Ferrone and Robert L. Ferris.
“Society for immunotherapy of cancer”: 2012. Epidermal Growth Factor Receptor Signaling Facilitates Immune Escape Function in Head and Neck Cancer .Raghvendra M. Srivastava*, Jie Hyun-bae*, Soldano Ferrone*, Robert L. Ferris*. *Department of Otolaryngology, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA; Surgery, Pathology, Immunology, University of Pittsburgh, Pittsburgh, PA. Head and neck cancer (HNC). J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 782.
“Society for immunotherapy of cancer”: 2012. Oct.24-28rth 2012, at Bethesda, MD. (Poster presentation). Poster abstract # 181. Raghvendra M. Srivastava, Jie Hyun-bae, Soldano Ferrone, Robert L. Ferris.
“Society for immunotherapy of cancer”: 2012. A Study of Immune Mechanisms of Action of Anti-epidermal Growth Factor Receptor Antibodies Cetuximab and Panitumumab and its Implication in Head and Neck Cancer Therapy, Raghvendra M. Srivastava*, Sandra P. Gibson*, Andres Lopez- Albaitero*, Jie Hyun-bae*, Soldao Ferronewzy, Robert L. Ferris*. *Otolaryngology, University of Pittsburgh, Pittsburgh, PA; Surgery, University of Pittsburgh, Pittsburgh, PA; Pathology, University of Pittsburgh, Pittsburgh, PA; Immunology, University of Pittsburgh, Pittsburgh, PA.J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 782.
“Society for immunotherapy of cancer”: 2012. Abstract. Inhibitory Receptors on Tumor Infiltrating Lymphocytes Reflect Aberrant TCR Triggering in the Tumor Microenvironment, Hyun-Bae Jie, Raghvendra Srivastava, Sandra Gibson, Robert L Ferris. Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA. Published in J Immunotherapy, Volume 35, Number 9, November–December 2012.p.786.
“Society for immunotherapy of cancer”: 2012. Abstract. Enrichment of CTLA4+CD39+CD25+FOXP3+ Regulatory T Cells in Head and Neck Cancer Patients is Promoted by Therapy With Cetuximab and Correlated With Clinical Outcome. Hyun-Bae Jie*, Patrick J. Schuler*, Fernando Concha-Benavente*, Raghvendra Srivastava*, Steve Lee*, Robert L. Ferris*. *Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA; Otorhinolaryngology, University Duisburg-Essen, Essen, Germany. J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 777.
“Society for immunotherapy of cancer”: 2012. Abstract. Enrichment of CTLA4+CD39+CD25+FOXP3+ Regulatory T Cells in Head and Neck Cancer Patients is Promoted by Therapy With Cetuximab and Correlated With Clinical Outcome. Hyun-Bae Jie*, Patrick J. Schuler*, Fernando Concha-Benavente*, Raghvendra Srivastava*, Steve Lee*, Robert L. Ferris*. *Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA; Otorhinolaryngology, University Duisburg-Essen, Essen, Germany. J Immunotherapy, Volume 35, Number 9, November–December 2012. Page 777.
Poster presentation at University of Pittsburgh Cancer Institute Retreat: 2012, June 14, 2013 sponsored by UPCI.
Poster presentation at University of Pittsburgh Cancer Institute Retreat: 2012, June 21-22, 2012 sponsored by UPCI.
“Society for immunotherapy of cancer”: 2012.Oct.24-28th 2012, Bethesda, MD. (Poster presentation).
Poster presentation at University of Pittsburgh Cancer Institute Retreat: 2012. June 21-22, 2012 sponsored by UPCI.
Immunology series seminar at University of Pittsburgh: 2010. Nov18, 2010, Cetuximab activated NK cells enhance DC cross-priming of tumor antigen.
Current Trend in Drug Discovery Research: 2007. Feb 17-21st, 2007 at Central Drug research Institute, Lucknow (Poster presentation)
“All India Cell Biology Conference on Genome Biology”: 2004. held on Dec.1-3rd 2004, at Punjab University, Chandigarh.(Poster presentation)
“Current Excitement in Biology”: 2002. Nov. 24-30th 2002 at Centre for cellular and molecular biology, Hyderabad.
"Poster presentation on ‘National Science Day’: 2000. Feb 8rth, 2000 sponsored by Department of Biotechnology, Govt. of India at BHU Varanasi and won the first prize.
